Published • loading... • Updated
Corrixr Therapeutics Names Malone CEO as Cancer Program Nears Clinical Testing
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Corrixr Therapeutics Names Malone CEO as Cancer Program Nears Clinical Testing
NEWARK, DE — Corrixr Therapeutics has appointed biotechnology executive Hilary M. Malone as chief executive officer as the gene-editing company prepares to advance its lead cancer therapy candidate into regulatory review and initial human testing. Malone succeeds company founder Eric B. Kmiec, who will remain chief scientific officer while continuing to oversee the scientific direction of the company, Corrixr announced. The leadership transition…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
